Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccines & Immunizations








U.S. Vaccine Names						Print
																Related Pages
										Print-friendly version of this chart [4 pages] can be found in the Epidemiology of Vaccine-Preventable Diseases textbook.
ACIP’s recommended vaccines listU.S. Vaccines: Table 1
(For Combination Vaccines, See Table 2)
Table 1: Vaccine Names, Abbreviations, Trade Names, and Manufacturers
Vaccine
Trade Name
Abbreviation
Manufacturer
Route
Doses in Routine Series
Approved Ages
CommentsAdenovirus
Adenovirus
Type 4 & Type 7

Barr Labs Inc.
Oral
(2 Tablets)
1
17-50 years
Live: Approved for military populationsAnthrax
BioThrax®
AVA
Emergent BioSolutions
IM
3
18-65 years
Inactivated, Adj.Cholera
Vaxchora®

PaxVax
Oral (Liquid)
1
18-64 years
Live AttenuatedCOVID-19
Comirnaty®
1vCOV-mRNA
Pfizer
IM
2
≥12 years
mRNASPIKEVAX®
1vCOV-mRNA
ModernaTx
IM
2
≥18 years
mRNADengue
Dengvaxia®
DEN4CYD
Sanofi
SC
3
9-16 years
Live RecombinantDTaP
Daptacel®
DTaP
Sanofi
IM
5
6 weeks-6 years
Inactivated, Adj.Infanrix®
DTaP
GlaxoSmithKline
IM
5
6 weeks-6 years
Inactivated, Adj.DT
Generic
DT
Sanofi
IM
5
6 weeks-6 years
Inactivated, Adj.: Use when pertussis is contraindicated*Haemophilus influenzae* type b (Hib)
ActHIB®
Hib (PRP-T)
Sanofi
IM
4
2 months-5 years
Inactivated, Adj.
(Tetanus toxoid conjugate)Hiberix®
Hib (PRP-T)
GlaxoSmithKline
IM
4
6 weeks-4 years
Inactivated, Adj.
(Tetanus toxoid conjugate)PedvaxHIB®
Hib (PRP-OMP)
Merck
IM
3
2-71 months
Inactivated, Adj.
(Meningococcal conjugate)Hepatitis A
Havrix®
HepA
GlaxoSmithKline
IM
2
Pediatric:
12 months-18 years
Adult: ≥19 years
Inactivated, Adj.Vaqta®
HepA
Merck
IM
2
Pediatric:
12 months-18 years
Adult: ≥19 years
Inactivated, Adj.Hepatitis B
Engerix-B®
HepB
GlaxoSmithKline
IM
3
Pediatric:
Birth-19 years
Adult: ≥20 years
Recombinant, Adj.Recombivax HB®
HepB
Merck
IM
3
Pediatric:
Birth-19 years
Adult: ≥20 years
Recombinant, Adj.Heplisav-B®
HepB
Dynavax Technologies
IM
2
≥18 years
Recombinant, Adj.Herpes Zoster (Shingles)
Shingrix®
RZV
GlaxoSmithKline
IM
2
≥50 years
Recombinant, Adj.Human Papillomavirus
(HPV)
Gardasil® 9
9vHPV
Merck
IM
2 or 3
9-45 years
Recombinant, Adj.
ACIP recommends 9-26 yearsInfluenza
Afluria®
IIV3
IIV4
Seqirus
IM
1 or 2
≥5 years
InactivatedFluad®
IIV3
Seqirus
IM
1
≥65 years
Inactivated, Adj.Fluarix®
IIV4
GlaxoSmithKline
IM
1 or 2
≥6 months
InactivatedFlublok®
RIV4
Sanofi
IM
1
≥18 years
Recombinant, Egg-FreeFlucelvax®
ccIIV4
Seqirus
IM
1 or 2
≥4 years
Cell-CultureFluLaval®
IIV4
GlaxoSmithKline
IM
1 or 2
≥6 months
InactivatedFluMist®
LAIV4
Medimmune
Intranasal
1 or 2
2-49 years
Live AttenuatedFluzone®
IIV3
IIV4
Sanofi
IM
1 or 2
≥6 months
InactivatedFluzone®
High-Dose
IIV3
Sanofi
IM
1
≥65 years
InactivatedJapanese encephalitis
Ixiaro®
JE
Valneva
IM
2
≥2 months
Inactivated, Adj.Measles, Mumps, Rubella
M-M-R® II
MMR
Merck
SC
2
≥12 months
Live AttenuatedMeningococcal
Menactra®
MCV4
MenACWY-D
Sanofi
IM
2
9 months-55 years
Inactivated (Diphtheria toxoid conjugate)Menveo®
MCV4
MenACWY-CRM
GlaxoSmithKline
IM
2
2 months-55 years
Inactivated
(CRM197 conjugate)Trumenba®
MenB-FHbp
Pfizer
IM
2 or 3
10-25 years
Recombinant, Adj.Bexsero®
MenB-4C
GlaxoSmithKline
IM
2
10-25 years
Recombinant, Adj.Pneumococcal
Pneumovax® 23
PPSV23
Merck
IM or SC
1
≥2 years
Inactivated PolysaccharidePrevnar 13®
PCV13
Pfizer
IM
4
≥6 weeks
Inactivated, Adj.
(CRM197 conjugate)Polio
Ipol®
IPV
Sanofi
IM or SC
4
≥6 weeks
InactivatedRabies
Imovax® Rabies

Sanofi
IM
3 (pre-exposure)
5 (post-exposure)
All ages
InactivatedRabAvert®

GlaxoSmithKline
IM
3 (pre-exposure)
5 (post-exposure)
All ages
InactivatedRotavirus
RotaTeq®
RV5
Merck
Oral (Liquid)
3
6-32 weeks
Live, PentavalentRotarix®
RV1
GlaxoSmithKline
Oral (Liquid)
2
6-24 weeks
Live, MonovalentTetanus,
(reduced) Diphtheria
Tenivac®
Td
Sanofi
IM
1 (Every 10 years)
≥7 years
Inactivated, Adj.(Generic)
Td
Massachusetts Biological Labs
IM
1 (Every 10 years)
≥7 years
Inactivated, Adj.Tetanus, (reduced) Diphtheria,
(reduced) Pertussis
Boostrix®
Tdap
GlaxoSmithKline
IM
1
≥10 years
Inactivated, Adj.Adacel®
Tdap
Sanofi
IM
1
10-64 years
Inactivated, Adj.Typhoid
Typhim Vi®

Sanofi
IM
1
≥2 years
Inactivated, PolysaccharideVivotif®

PaxVax
Oral (Capsules)
4
≥6 years
Live AttenuatedVaricella
Varivax®
VAR
Merck
SC
2
≥12 months
Live AttenuatedVaccinia (Smallpox)
ACAM2000®

Sanofi
Percutaneous
1
All ages
Live AttenuatedYellow Fever
YF-Vax®
YF
Sanofi
SC
1
≥9 months
Live AttenuatedShow More
U.S. Vaccines: Table 2
(Combination Vaccines)
Table 2: Vaccine Names, Abbreviations, Trade Names, and Manufacturers, Combination Vaccines
Vaccine
Trade Name
Abbreviation
Manufacturer
Route
Doses in Routine Series
Approved Ages
CommentsDTaP, Polio
Kinrix®
DTaP-IPV
GlaxoSmithKline
IM
1
4-6 years
Inactivated, Adj.: Approved as 5th DTaP and 4th IPV.Quadracel®
DTaP-IPV
Sanofi
IM
1
4-6 years
Inactivated, Adj.: Approved as 5th DTaP and 4th IPV.DTaP, Hepatitis B, Polio
Pediarix®
DTaP-HepB-IPV
GlaxoSmithKline
IM
3
6 weeks-6 years
Inactivated, Adj.: Approved for 2, 4, 6 month doses.DTaP, Polio, *Haemophilus influenzae*type b
Pentacel®
DTaP-IPV/Hib
Sanofi
IM
4
6 weeks-4 years
Inactivated, Adj.: Approved for 2, 4, 6, 15-18 month doses.**DTaP, Polio, *Haemophilus influenzae*type b, Hepatitis B**
Vaxelis®
DTap-IPV-Hib-HepB
Sanofi
IM
3
6 weeks-4 years
RecombinantHepatitis A, Hepatitis B
Twinrix®
HepA-HepB
GlaxoSmithKline
IM
3
≥18 years
Inactivated/Recombinant, Adj.
Pediatric HepA + Adult HepBMeasles, Mumps, Rubella, Varicella
ProQuad®
MMRV
Merck
SC
2
12 months-
12 years
Live AttenuatedShow More
Notes
The abbreviations on this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the *Morbidity and Mortality Weekly Report* (*MMWR*), the editor of *Epidemiology and Prevention of Vaccine-Preventable Diseases* (the *Pink Book*), ACIP members, and liaison organizations to the ACIP. These abbreviations are intended to provide a uniform approach to vaccine references used in ACIP Recommendations and Policy Notes published in the *MMWR*, the *Pink Book*, and the American Academy of Pediatrics *Red Book*, and in the U.S. immunization schedules for children, adolescents, and adults. In descriptions of combination vaccines, a hyphen (-) indicates products in which the active components are supplied in their final (combined) form by the manufacturer; a slash ( / ) indicates products in which active components must be mixed by the user.
“Doses in a Routine Series” (Column 6) reflects doses administered to a healthy patient at the recommended ages. It doesn’t necessarily reflect schedules for patients with health conditions or other high-risk factors, alternative schedules, catch-up schedules, or booster doses not part of an initial series. For some combination vaccines, this column represents the routine number of doses *for that product*, and not necessarily the total number of doses in a complete series for the components. (For example, Kinrix® or Quadracel® may be used for only 1 dose of multi-dose DTaP and IPV series.)
“Adj.” in the “Comments” column indicates that the vaccine contains an adjuvant.
A hyphen in an age range means “through” (i.e., “6 weeks-6 years” means 6 weeks through 6 years [to the 7th birthday]).Top of Page
							
					
							Last Reviewed:  March 26, 2019						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeVaccines and Immunizations Home
For Parents
For Adults
For Pregnant Women
For Healthcare Professionals
COVID-19 Vaccinationplus icon
Product Info by US Vaccineplus icon
Janssen/J&J Vaccine
Clinical Careplus icon
COVID-19 Vaccines
Managing Anaphylaxis
Myocarditis and Pericarditis Considerations
Lab Tests After Severe Allergic Reaction
Provider Requirements and Support
Vaccine Recipient Educationplus icon
How to talk to your patients about COVID-19 vaccination
Health Departments
Planning & Partnerships
COVID-19 Vaccine Data Systems
Vaccinate with Confidence
For Immunization Managers
Basics and Common Questionsplus icon
Immunization: The Basics
What’s in Vaccines
Immunity Types
Vaccines and Preventable Diseases
How Vaccines are Developed and Approved for Use
Content Syndication
Communication Resources
News and Media Resourcesplus icon
News
Newsletters
Events


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue